Kidney Transplant; Complications

Nephrology
5
Pipeline Programs
4
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Veloxis Pharmaceuticals
4 programs
1
3
EnvarsusPhase 41 trial
Extended Release Tacrolimus TabletsPhase 41 trial
Once daily immunosuppression regimenPhase 41 trial
Tacrolimus, Extended Release,Phase 11 trial
Active Trials
NCT03410654CompletedEst. Jul 2024
NCT03461445CompletedEst. Jul 2023
NCT03841097Active Not RecruitingEst. May 2026
+1 more trials
Bayer
BayerLEVERKUSEN, Germany
1 program
1
Finerenone Oral TabletPhase 21 trial
Active Trials
NCT06059664Recruiting150Est. Sep 2027
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
Bioimpedance SpectroscopyN/A1 trial
Active Trials
NCT04451356UnknownEst. Dec 2022
Genomics
GenomicsUK - Oxford
1 program
TruGraf testN/A1 trial
Active Trials
NCT04280276Terminated13Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Veloxis PharmaceuticalsExtended Release Tacrolimus Tablets
Veloxis PharmaceuticalsOnce daily immunosuppression regimen
Veloxis PharmaceuticalsEnvarsus
BayerFinerenone Oral Tablet
Veloxis PharmaceuticalsTacrolimus, Extended Release,
GenomicsTruGraf test
T-TherapeuticsBioimpedance Spectroscopy

Clinical Trials (7)

Total enrollment: 163 patients across 7 trials

NCT03841097Veloxis PharmaceuticalsExtended Release Tacrolimus Tablets

Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants

Start: Nov 2019Est. completion: May 2026
Phase 4Active Not Recruiting
NCT03555448Veloxis PharmaceuticalsOnce daily immunosuppression regimen

Once Daily Immunosuppression Regimen

Start: Jun 2018Est. completion: Nov 2023
Phase 4Terminated
NCT03461445Veloxis PharmaceuticalsEnvarsus

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

Start: Apr 2018Est. completion: Jul 2023
Phase 4Completed
NCT06059664BayerFinerenone Oral Tablet

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

Start: Apr 2024Est. completion: Sep 2027150 patients
Phase 2Recruiting
NCT03410654Veloxis PharmaceuticalsTacrolimus, Extended Release,

Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.

Start: Oct 2018Est. completion: Jul 2024
Phase 1Completed
NCT04280276GenomicsTruGraf test

TruGraf Utilization in High IPV Levels

Start: Mar 2020Est. completion: Mar 202213 patients
N/ATerminated
NCT04451356T-TherapeuticsBioimpedance Spectroscopy

Romanian Kidney Transplant Cardiovascular Risk Registry

Start: Feb 2020Est. completion: Dec 2022
N/AUnknown

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 163 patients
4 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)